Actively Recruiting
Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer
Led by Xiaorong Hou · Updated on 2025-08-11
20
Participants Needed
1
Research Sites
287 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
1. Study Type: Single-center, single-arm, prospective study. 2. Sample Size: 20 patients with high-risk endometrial cancer were enrolled. 3. Treatment Procedure: The existing clinical oART (Online Adaptive Radiotherapy) workflow protocol for malignant tumors used in our department was applied. Procedures included simulation, target volume delineation, radiotherapy planning, and treatment delivery. External beam radiation therapy (EBRT) was delivered using moderate hypofractionation. If indicated, brachytherapy was performed after the completion of EBRT. When combined with chemotherapy, radiotherapy could be administered during chemotherapy intervals or after completion of chemotherapy. 4. Study Endpoints: Primary Endpoint: Incidence of acute toxicity. Secondary Endpoints: 3-year failure-free survival (FFS) rate, incidence of chronic toxicity, quality of life (QoL), treatment costs, etc.
CONDITIONS
Official Title
Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years old
- ECOG performance status score of 0 to 2
- Willing to follow the online adaptive radiotherapy workflow
- Had total hysterectomy and bilateral salpingo-oophorectomy, with or without pelvic and/or para-aortic lymph node dissection or sentinel lymph node biopsy
- Pathological staging and histology matching specified high-risk endometrial cancer types and stages per FIGO 2009
- Patients and families understand the study protocol and voluntarily sign informed consent
You will not qualify if you...
- History of prior abdominal or pelvic radiation therapy
- More than 12 weeks between surgery and radiotherapy start if no chemotherapy was given
- More than 6 months between surgery and radiotherapy start if chemotherapy was given
- Previous diagnosis of other cancers
- Pregnant or breastfeeding women
- Current fever or uncontrolled active infection
- History of inflammatory bowel disease
- Severe health conditions affecting study participation such as unstable heart disease, kidney problems, chronic hepatitis, poorly controlled diabetes, or psychiatric disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
X
Xiaorong Hou, Professor
CONTACT
Z
Zihan Yan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here